FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1908826089> ?p ?o ?g. }

• W1908826089 endingPage "191" @default.
• W1908826089 startingPage "190" @default.
• W1908826089 abstract "γ-Aminobutyric acid (GABA)-analogue medications, including gabapentin and pregabalin, are recommended first-line treatments for neuropathic pain in the UK 1, and pregabalin has been used in the treatment of various psychiatric conditions, including generalized and social anxiety disorders 2. Consequently, there has been a large increase in prescription of these drugs over the last decade 3. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) recently highlighted early reports from pharmacovigilance data from four countries, including the UK, regarding the potential for misuse of these medications and indications from toxicological analyses of the involvement of these medications in deaths of users 4. There is also concern regarding their access from online pharmacies and misuse of legitimately prescribed medication 5. Furthermore, dependent users of recreational drugs may seek access to these medications in an attempt to prevent or treat withdrawal symptoms 3, 6, 7. However, to date there have been no data reported on the prevalence of the misuse of these medications in any country. The aim of this study was to determine the prevalence, frequency and sources of misuse of the GABA analogues (baclofen, gabapentin and pregabalin) in the UK. We partnered with a global market research company, GMI (http://www.gmi-mr.com/global-panel), which has an established global consumer panel of millions of persons. We devised a question-based survey that was formulated by the company into an Internet-based survey (see Appendix S1). Invitations were sent by GMI to existing market research panel members in the UK only, between the ages of 16 and 59 years, and respondents were capped at a maximum of 1500. The raw data of the responses to the questions were given to us, linked to a fully anonymized unique personal identifier. Basic demographics were collected together with data on lifetime prevalence and frequency of misuse of baclofen, gabapentin and pregabalin; where individuals had misused one of these drugs, they were asked to indicate the source(s) of supply for misuse. We included questions based on lifetime prevalence of use of recreational drugs [cocaine, cannabis and 3,4-methylenedioxy-N-methylamphetamine (MDMA, ‘ecstasy’)] so that we could benchmark against existing national data provided by the 2011/2012 Crime Survey for England and Wales 8. In this way, we could confirm that our survey population provided a reasonable sample of the national population in the UK with respect to recreational drug use and therefore medications misuse. The online survey was completed by 1500 individuals [male, 49.1% (n = 737) and female, 50.9% (n = 763)]; 9.1, 40.5, 21.1 and 29.3% were aged 16–20, 21–39, 40–49 and 50–59 years old, respectively. Lifetime prevalence of use of recreational drugs was comparable to national data from the 2011/2012 Crime Survey for England and Wales. Within the survey cohort, self-reported lifetime prevalence of use of cocaine was 8.1%, cannabis 28.1% and MDMA 8.2%; compared with 9.5, 31.0 and 8.6%, respectively, for the three recreational drugs in the 2011/2012 Crime Survey for England and Wales 7. The lifetime prevalence of misuse of any of the three surveyed GABA-analogue medications was 2.5% (n = 38); for each drug, this was 1.3% (n = 19) for baclofen, 1.1% (n = 17) for gabapentin, and 0.5% (n = 8) for pregabalin. The frequency of misuse was less than once monthly in 36.8% (n = 14), between once monthly and once weekly in 50% (n = 19), and more than once weekly in 13.1% (n = 5). Of the people misusing these medications, 36.8% (n = 14) obtained their supply from multiple sources, with similar rates of sourcing overall from health services (63.1%, n = 24), from family or acquaintances (57.8%, n = 22) and from the Internet (47.3%, n = 18), with only 7.8% (n = 3) obtaining the medication from abroad. Misuse of medication that had been legitimately prescribed to the individual was the sole source for only 13.1% (n = 5). This study, to our knowledge, is the first report to estimate the prevalence of misuse of GABA-analogue medications conducted in a cohort with similar lifetime prevalence of use of recreational drugs to the UK population. Whilst we did not confirm substance misuse by structured interview or specific analysis, our results suggest that there is appreciable misuse of baclofen, gabapentin and pregabalin in the UK, with approximately one in 40 of survey respondents self-reporting misuse of any of the GABA-analogue medications. The provenance of the majority of misuse appears to be from sources other than legitimately prescribed medication, which has important implications for future strategies to reduce access to these medications. Similar surveys can be used to determine the robustness of early pharmacovigilance data, such as that provided by the EMCDDA, to help regulatory and law-enforcement agencies understand the epidemiology of substance misuse and decide whether further control and/ or monitoring on supply and use is required. In addition, further work is needed to understand the reasons for misuse, to enable appropriately targeted harm-reduction activities through multi-agency responses. All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work. Appendix S1 Internet-based questionnaire Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article." @default.
• W1908826089 created "2016-06-24" @default.
• W1908826089 creator A5015960673 @default.
• W1908826089 creator A5017272739 @default.
• W1908826089 creator A5027524322 @default.
• W1908826089 creator A5049983183 @default.
• W1908826089 date "2014-06-20" @default.
• W1908826089 modified "2023-10-03" @default.
• W1908826089 title "Misuse of the γ-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK" @default.
• W1908826089 cites W1977980816 @default.
• W1908826089 cites W1994385429 @default.
• W1908826089 cites W2038477728 @default.
• W1908826089 cites W2148930083 @default.
• W1908826089 doi "https://doi.org/10.1111/bcp.12277" @default.
• W1908826089 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4168395" @default.
• W1908826089 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25083536" @default.
• W1908826089 hasPublicationYear "2014" @default.
• W1908826089 type Work @default.
• W1908826089 sameAs 1908826089 @default.
• W1908826089 citedByCount "75" @default.
• W1908826089 countsByYear W19088260892014 @default.
• W1908826089 countsByYear W19088260892015 @default.
• W1908826089 countsByYear W19088260892016 @default.
• W1908826089 countsByYear W19088260892017 @default.
• W1908826089 countsByYear W19088260892018 @default.
• W1908826089 countsByYear W19088260892019 @default.
• W1908826089 countsByYear W19088260892020 @default.
• W1908826089 countsByYear W19088260892021 @default.
• W1908826089 countsByYear W19088260892022 @default.
• W1908826089 countsByYear W19088260892023 @default.
• W1908826089 crossrefType "journal-article" @default.
• W1908826089 hasAuthorship W1908826089A5015960673 @default.
• W1908826089 hasAuthorship W1908826089A5017272739 @default.
• W1908826089 hasAuthorship W1908826089A5027524322 @default.
• W1908826089 hasAuthorship W1908826089A5049983183 @default.
• W1908826089 hasBestOaLocation W19088260891 @default.
• W1908826089 hasConcept C118552586 @default.
• W1908826089 hasConcept C126322002 @default.
• W1908826089 hasConcept C142724271 @default.
• W1908826089 hasConcept C170493617 @default.
• W1908826089 hasConcept C204787440 @default.
• W1908826089 hasConcept C2426938 @default.
• W1908826089 hasConcept C2775858608 @default.
• W1908826089 hasConcept C2776468701 @default.
• W1908826089 hasConcept C2776608144 @default.
• W1908826089 hasConcept C2777107010 @default.
• W1908826089 hasConcept C2777683783 @default.
• W1908826089 hasConcept C2778186239 @default.
• W1908826089 hasConcept C2778938600 @default.
• W1908826089 hasConcept C2780035454 @default.
• W1908826089 hasConcept C2780837902 @default.
• W1908826089 hasConcept C2781201050 @default.
• W1908826089 hasConcept C48856860 @default.
• W1908826089 hasConcept C558461103 @default.
• W1908826089 hasConcept C57658597 @default.
• W1908826089 hasConcept C71924100 @default.
• W1908826089 hasConcept C98274493 @default.
• W1908826089 hasConceptScore W1908826089C118552586 @default.
• W1908826089 hasConceptScore W1908826089C126322002 @default.
• W1908826089 hasConceptScore W1908826089C142724271 @default.
• W1908826089 hasConceptScore W1908826089C170493617 @default.
• W1908826089 hasConceptScore W1908826089C204787440 @default.
• W1908826089 hasConceptScore W1908826089C2426938 @default.
• W1908826089 hasConceptScore W1908826089C2775858608 @default.
• W1908826089 hasConceptScore W1908826089C2776468701 @default.
• W1908826089 hasConceptScore W1908826089C2776608144 @default.
• W1908826089 hasConceptScore W1908826089C2777107010 @default.
• W1908826089 hasConceptScore W1908826089C2777683783 @default.
• W1908826089 hasConceptScore W1908826089C2778186239 @default.
• W1908826089 hasConceptScore W1908826089C2778938600 @default.
• W1908826089 hasConceptScore W1908826089C2780035454 @default.
• W1908826089 hasConceptScore W1908826089C2780837902 @default.
• W1908826089 hasConceptScore W1908826089C2781201050 @default.
• W1908826089 hasConceptScore W1908826089C48856860 @default.
• W1908826089 hasConceptScore W1908826089C558461103 @default.
• W1908826089 hasConceptScore W1908826089C57658597 @default.
• W1908826089 hasConceptScore W1908826089C71924100 @default.
• W1908826089 hasConceptScore W1908826089C98274493 @default.
• W1908826089 hasIssue "1" @default.
• W1908826089 hasLocation W19088260891 @default.
• W1908826089 hasLocation W19088260892 @default.
• W1908826089 hasLocation W19088260893 @default.
• W1908826089 hasLocation W19088260894 @default.
• W1908826089 hasOpenAccess W1908826089 @default.
• W1908826089 hasPrimaryLocation W19088260891 @default.
• W1908826089 hasRelatedWork W1493169759 @default.
• W1908826089 hasRelatedWork W1908826089 @default.
• W1908826089 hasRelatedWork W2067402286 @default.
• W1908826089 hasRelatedWork W2080867598 @default.
• W1908826089 hasRelatedWork W2088733710 @default.
• W1908826089 hasRelatedWork W2309932814 @default.
• W1908826089 hasRelatedWork W2554452413 @default.
• W1908826089 hasRelatedWork W2935114587 @default.
• W1908826089 hasRelatedWork W3023891549 @default.
• W1908826089 hasRelatedWork W4300502925 @default.
• W1908826089 hasVolume "78" @default.
• W1908826089 isParatext "false" @default.
• W1908826089 isRetracted "false" @default.

• next